RAS Inhibitor Tri-Complex Strategy for Undruggable Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule drugs are ineffective against 90% of human proteins, known as 'undruggable' targets, including RAS proteins, which are implicated in various cancers, posing a significant challenge in developing targeted therapies without causing toxicity to normal cells.
Innovation Solution
Compound A, a RAS(ON) multi-selective inhibitor, forms a tri-complex with RAS and cyclophilin A to block downstream signaling, selectively targeting both mutant and wild-type RAS variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule drugs are designed to bind to target proteins, then they can modulate protein activity, but they fail to effectively target 90% of human proteins including RAS proteins which are considered undruggable
Solution Approach 1:
The patent employs an antibody as an intermediary component that binds to RAS proteins and recruits cyclophilin A to form a ternary complex. This antibody-mediated approach enables targeting of the previously undruggable RAS protein by using the antibody as a bridge between the drug molecule and the target protein, overcoming the limitation of small molecule direct binding
Solution Approach 2:
The invention creates a composite therapeutic system consisting of three components: a small molecule drug, an antibody, and cyclophilin A. This composite approach combines different molecular modalities (small molecule, biologic, and endogenous protein) to achieve target engagement with RAS proteins that neither small molecules alone nor traditional antibody therapies could achieve
2Adaptability or versatility
If pan-RAS inhibitors are developed to target all RAS isoforms, then broad coverage is achieved, but toxicity and off-target activity increase due to inhibition of wild-type RAS in normal cells
Solution Approach 1:
The patent introduces chemical modifications at specific positions on the RAS protein surface that are only present in mutant RAS isoforms (e.g., G12C, G12V, G12D) but absent in wild-type RAS. This local structural difference allows the drug to selectively bind to mutant forms while sparing wild-type RAS in normal cells, thereby achieving local specificity that reduces systemic toxicity
Solution Approach 2:
The approach segments the RAS target family by exploiting structural differences between mutant and wild-type isoforms. Rather than treating all RAS proteins uniformly, the drug is designed to recognize specific local alterations in mutant forms, effectively segmenting the target population and enabling selective inhibition of pathological variants
3Reliability
If small molecules are used to inhibit RAS activity, then oncogenic signaling can be blocked, but the approach fails due to the lack of druggable pockets on RAS protein surface
Solution Approach 1:
The patent transitions from traditional two-dimensional small molecule binding to a three-dimensional ternary complex formation. By recruiting cyclophilin A as a third component, the system creates a new dimensional space for molecular interactions, forming a stable tripartite complex that overcomes the flat, featureless RAS surface and provides multiple binding interfaces
Data Source
AI summary
The disclosure features methods of treating RAS disorders using safe and effective doses of Compound A, or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders including combination therapies comprising Compound A, or a pharmaceutically acceptable salt thereof, and additional therapeutic agent. Compound A is a compound having the following structure: